1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Minute Insight: Abbott’s Libre 3 Finds Route To NHS Patients With YpsoMed And CamDiab Partnership

 
• By Barnaby Pickering

Abbott’s flagship CGM, the FreeStyle Libre 3, will soon become available in the UK through the National Health Service as part of a hybrid closed-loop system utilizing Ypsomed and CamDiab’s technologies.  

Minute Insight
• Source: Informa/Alamy

Abbott Laboratories’ FreeStyle Libre 3 continuous glucose monitor (CGM) is now authorized in the UK to be used with Ypsomed’s YpsoPump and CamDiab’s CamAPS FX mobile app in type I diabetics.

Patients will be able to access the system through the NHS.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

More from Device Area

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 
• By Brian Bossetta

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.

With CMS Coverage Established, Medtronic Looks To Next Steps For Renal Denervation

 
• By Elizabeth Orr

US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 
• By Natasha Barrow

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.